Last updated: 2026-09-06 13:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
EyePoint, Inc. (EYPT) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NASDAQ. The stock is currently priced at $4.57, with a market capitalisation of $412.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.95 to $19.11. This page covers its latest market performance, valuation, price trends and company information.
$412.96M | |
$4.53 | |
$39.40 | |
$2.19 | |
$4.57 | |
1.61M | |
-- | |
-- | |
$19.11 | |
$3.95 | |
-- | |
-- |
EyePoint, Inc. (EYPT) last closed at $4.57 as of 2026-09-04 23:47:00, unchanged from the previous close of $4.57.
During the latest regular trading session, EYPT traded between $2.19 and $39.40, with a volume of 1.61M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, EyePoint, Inc. (EYPT) moved from $4.44 to $4.57, representing a gain of 3.02% ($0.13).
The stock traded between $4.50 and $4.68 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 3.77 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.1%
EYPT is currently trading at $4.57, placing it 4.1% of the way from its 52-week low of $3.95 to its 52-week high of $19.11. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 214 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of EyePoint, Inc. (EYPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.